BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 14, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/11 cls
Advanced Life (NASDAQ:ADLS) Lazard Matthew Osborne Upgrade Buy (from hold) 10% $1.21
Osborne set a $4 target after the company announced it will submit next quarter an NDA for cethromycin to treat mild to moderate community acquired pneumonia (CAP). He believes the company is undervalued relative to the net present value of the cash flow it can receive upon launch of the ketolide antibiotic, and expects sales to peak at $350-$400M by 2014. He also thinks a partnership is imminent (see B9).
Celgene (NASDAQ:CELG) Cowen Rachel McMinn Other Neutral -3% $62.66
McMinn raised her FY08 and FY09 revenue estimates to $2.24B from $2.19B and to $3.01B from $2.95B, respectively, on the strength of the euro and European sales. McMinn also lowered her FY08 EPS estimate to $1.54 from $1.56 after building higher integration costs associated with the acquisition of Pharmion into her model, but raised her FY09 EPS...

Read the full 912 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >